[Postsurgical adjuvant immunotherapy against primary non-small cell lung cancer]

Area of Science:

• Oncology
• Immunotherapy
• Surgical Oncology

Background:

• Lung cancer prognosis remains poor post-resection due to micrometastases.
• Local therapies often fail to eradicate all disseminated cancer cells.
• Current treatments necessitate improved strategies to enhance patient survival.

Purpose of the Study:

• To evaluate the efficacy of a multimodality therapy for non-small cell lung cancer (NSCLC).
• To assess the impact of combining surgery, chemotherapy, and adoptive immunotherapy on patient survival.
• To determine if interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cell therapy improves outcomes compared to standard care.

Main Methods:

• A randomized study was conducted involving NSCLC patients.
• Participants received a combination therapy including surgery, chemotherapy, and adoptive immunotherapy with IL-2 and LAK cells.
• A control group received standard treatment without the immunotherapy component.

Main Results:

• The group receiving IL-2 and LAK adoptive immunotherapy demonstrated a significantly higher survival rate.
• The multimodality approach showed a positive impact on patient survival compared to the control group.
• Adoptive immunotherapy effectively complemented surgery and chemotherapy.

Conclusions:

• Interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cell adoptive immunotherapy is an effective treatment modality for NSCLC.
• This immunotherapy approach compensates for the limitations of surgery and chemotherapy in treating lung cancer.
• The findings support IL-2, LAK adoptive immunotherapy as a promising strategy to improve lung cancer patient outcomes.